Clinical Impact of CDK4/6 Inhibitors in De Novo or PR− or Very Elderly Post-Menopausal ER+/HER2− Advanced Breast Cancers

Tang, Hiu; Yeo, Daniel; De Souza, Karen; Ahmad, Omar; Shafiq, Tahir; Ofor, Okezie; Anand, Anjana; Karim, Syed; Khan, Sarah; Madhusudan, Srinivasan

Abstract

The CDK4/6 inhibitors significantly increase progression-free survival (PFS) in ER+/HER2− advanced breast cancer patients. In clinical trials, overall survival (OS) improvement has been demonstrated for ribociclib and abemaciclib but not for palbociclib. We undertook a real-world evaluation of PFS and OS in 227 post-menopausal patients who received first-line CDK4/6 inhibitors. There is no significant difference in median PFS (27.5 months vs. 25.7 months, p = 0.3) or median OS (49.5 months vs. 50.2 months, p = 0.67) in patients who received either palbociclib or ribociclib, respectively. De novo disease is significantly associated with prolonged median PFS and median OS compared with recurrence disease (47.1 months vs. 20.3 months (p = 0.0002) and 77.4 months vs. 37.3 months (p = 0.0003), respectively). PR– tumours have significantly reduced median PFS and OS compared with PR+ disease (19.2 months vs. 38 months (p = 0.003) and 34.3 months vs. 62.6 months (p = 0.02), respectively). In the very elderly (>80 years), median PFS and OS are significantly shorter compared with patients who are 65 years or below (14.5 months vs. 30.2 months (p = 0.01), and 77.4 months vs. 29.6 months (p = 0.009), respectively) in the palbociclib group. Our data suggest that the benefit in the very elderly is limited, and PR+/de novo disease obtains the maximum survival benefit.

Citation

Tang, H., Yeo, D., De Souza, K., Ahmad, O., Shafiq, T., Ofor, O., …Madhusudan, S. (2023). Clinical Impact of CDK4/6 Inhibitors in De Novo or PR− or Very Elderly Post-Menopausal ER+/HER2− Advanced Breast Cancers. Cancers, 15(21), Article 5164. https://doi.org/10.3390/cancers15215164

• Journal Article Type: Article
• Acceptance Date: Oct 23, 2023
• Online Publication Date: Oct 26, 2023
• Publication Date: Nov 1, 2023
• Deposit Date: Nov 4, 2023
• Publicly Available Date: Nov 10, 2023
• Journal: Cancers
• Electronic ISSN: 2072-6694
• Publisher: MDPI
• Peer Reviewed: Peer Reviewed
• Volume: 15
• Issue: 21
• Article Number: 5164
• DOI: https://doi.org/10.3390/cancers15215164
• Keywords: advanced breast cancer; ER+/HER2− breast cancers; PR; CDK4/6 inhibitors; palbociclib; ribociclib; abemaciclib; PFS; OS
• Public URL: https://nottingham-repository.worktribe.com/output/26811853
• Publisher URL: https://www.mdpi.com/2072-6694/15/21/5164